Answers are grounded in this paper and cite their sources.
Case report documents treatment outcomes of mucinous adenocarcinoma in a young adult, revealing high recurrence rates, suggesting limited effectiveness of standard therapies.
Colorectal cancer (CRC) is the fourth most common cancer and the fifth leading cause of cancer-related mortality in Indonesia. An increasing incidence of CRC among young patients has been highlighted in several studies. Most reports showed that young patients with CRC were associated with specific clinicopathological characteristics, including more advanced tumor stage, poor histologic features, more mucinous tumors, high recurrence events, and poor responses to standard therapy. A 29-year-old woman presented with a lump in the anal region, hematochezia, and weight loss over two months. Histopathological examination after laparotomy and tumor resection revealed a moderately differentiated mucinous adenocarcinoma of the rectum, stagepT3N1cM0 (IIIB). She had received eight cycles of first-line chemotherapy with Capecitabine monotherapy, then second-line chemotherapy with the FOLFOX regimen for eight cycles, followed by concurrent chemoradiotherapy (CCRT) with Capecitabine, and finally eight cycles of third-line chemotherapy with theXELIRI regimen due to a residual rectosigmoid mass. Post-treatment evaluation showed she was asymptomatic, and an abdominal MSCT scan revealed no residual mass, indicating a complete clinical response. However, ten months later, she experienced recurrent symptoms, including hematochezia and a lump in the anal region. Biopsy of the lesion confirmed mucinous adenocarcinoma of the anorectum with clinical stage rT4bN1aM0 (IIIC). The mucinous subtype of adenocarcinoma is more common in younger patients and is generallyconsidered a poor prognostic factor. The limited response to therapy has been linked to a relatively hypoxic tumor environment caused by decreased blood supply, which may diminish the effectiveness of chemotherapy. The mucous layer and abundant mucin may also hinder the delivery of chemotherapy agentsand reduce the penetration of radiation. Biological factors such as mutations in KRAS and BRAF, overexpression of the MUC2 gene, and increased MSI or DNA MMR deficiency have been observed in mucinous cancers, playing an important role in determining treatment options.
No takes yet. Share an insight, caveat, or question.
Wahyuni et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: